

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 July 2022 (14.07.2022)



(10) International Publication Number
WO 2022/150516 A1

(51) International Patent Classification:

C12N 9/24 (2006.01) *A61K 39/395* (2006.01)
C12N 15/09 (2006.01) *A61K 39/44* (2006.01)
A01H 1/06 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2022/011499

(22) International Filing Date:

06 January 2022 (06.01.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/134,411 06 January 2021 (06.01.2021) US
63/217,998 02 July 2021 (02.07.2021) US

(71) Applicant: **PALLEON PHARMACEUTICALS INC.**

[US/US]: 266 Second Avenue, 2nd Floor, Waltham, Massachusetts 02451 (US).

(72) Inventors: **PENG, Li**; 6 Bicentennial Drive, Lexington,

Massachusetts 02421 (US). **CAO, Lizhi**; 23 Highland Avenue, Stoneham, Massachusetts 02180 (US). **SHELKE,**

Sandip A.; 55 Hill Road, Belmont, Massachusetts 02478 (US).

(74) Agent: **DAVENPORT, Andrew M.**; Goodwin Procter LLP, 100 Northern Avenue, IP Docketing Dept/7th Floor, Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*):

AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*):

ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: SIALIDASE-HER2-ANTIBODY FUSION PROTEINS AND METHODS OF USE THEREOF




FIGURE 2

(57) Abstract: The invention relates generally to recombinant sialidase and anti-HER2 immunoglobulin antigen-binding domain fusion proteins. The invention also provides antibody conjugates including a sialidase and an anti-HER2 antibody or a portion thereof. The invention further relates to methods of using the sialidase fusion proteins or antibody conjugates for treating cancer.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*